Fox Chase Cancer Center, Philadelphia, PA
Michael J. Hall , Paul D'Avanzo , Yana Chertock , Jesse A Brajuha , Sarah Bauerle Bass
Background: TGP is widely used to identify targetable mutations for precision cancer treatment and clinical trials. Many patients have poor understanding of TGP and are unaware of possible secondary hereditary risks. Lack of clarity regarding the relevance of informed consent and genetic counseling further magnify risks for patients. AA patients have lower genetic knowledge and health literacy and higher MM than Caucasian patients, making them especially vulnerable in the clinical setting. Perceptions of TGP in AA cancer patients have not been well-characterized. Methods: 120 AA pts from 1 suburban and 1 urban site (Fox Chase Cancer Center[FCCC] and Temple University Hospital[TUH]) were surveyed. A k-means cluster analysis using a modified MM scale was conducted; chi-square analysis assessed demographic differences. Perceptual mapping (PM)/multidimensional scaling and vector modeling was used to create 3-dimensional maps to study how TGP barriers/facilitators differed by MM group and how message strategies for communicating about TGP may also differ. Results: Data from 112 analyzable patients from FCCC (55%) and TUH (45%) were parsed into less MM (MM-L, n = 42, 37.5%) and more MM (MM-H, n = 70, 72.5%) clusters. MM-L and MM-H clusters were demographically indistinct with no significant associations by sex (p = 0.49), education (p = 0.3), income (p = 0.65), or location (p = 0.43); only age was significant (older = higher MM, p = 0.006). Patients in the MM-H cluster reported higher concerns about TGP, including cost (p < 0.001), insurance discrimination (p < 0.001), privacy breaches (p = 0.001), test performance/accuracy (p = 0.001), secondary gain by providers (p < 0.001) and provider ability to explain results (p = 0.04). Perceptual mapping identified both shared and contrasting barriers between MM clusters (Table). Conclusions: More than 2/3 of AA patients comprised a MM-H cluster. Communication strategies should focus on concerns about family and how to discuss TGP with an oncologist. PM can identify distinct and shared information needs of vulnerable populations undergoing TGP.
Less mistrust (MM-L) | Shared perceptions | More mistrust (MM-H) | |
---|---|---|---|
TGP concerns | Results are not accurate Genetic info may be used against me (i.e. insurance) because of my race | What TGP will find Results used for gain without me knowing Genetic info won't be private Minorities more likely to be discriminated against | Oncologist can't explain results so I understand TGP being done to get more money from me and insurance |
TGP benefits | Benefits outweigh risks Can benefit society | Can improve QoL | Can improve treatment options Can help treat cancer |
TGP and family | Would ask my family advice about TGP | Results could benefit family | Family will judge me for genetic testing |
Beliefs about provider | Trust of own oncologist Comfort talking to oncologist |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2021 ASCO Annual Meeting
First Author: Michael J. Hall
2023 ASCO Annual Meeting
First Author: Michael J. Hall
2021 ASCO Annual Meeting
First Author: Pedro C. Barata
2015 ASCO Annual Meeting
First Author: Michael J. Hall